Zedira
Key Facts
| Invested since | 2007 |
| Based in | Hesse |
About the company
Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.
Zedira in the news
Zum Artikel
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharmato Develop First-in-Class Celiac Disease Therapy
More startups from Life Sciences
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
Heidelberg Epignostix is a healthcare company whose mission is to transform cancer diagnostics through data science. The company has developed novel AI-based bioinformatics algorithms with utility in cancer classification for …
To the complete profileof Heidelberg Epignostix
Exit
Development of antibody conjugate-based cancer therapeutics for solid tumors with high unmet needs that are otherwise difficult to treat Problem: Solid cancers are still very difficult to treat. Most treatments …
To the complete profileof Emergence Therapeutics
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
MDA was founded in 2023 by Dr Gunter Trojandt, Annett Christ and two business angels, Jozsef Bugovics and Nils Kröber. MDA has a total of 10 employees and is based …
To the complete profileof Medical Decision Alliance
PerformaNat GmbH was founded in 2015 as a spin-off of the veterinary medicine department of the Freie Universität Berlin. The first product – an animal-feed additive for use with dairy …
To the complete profileof PerformaNat
IOP GmbH will initiate a paradigm chance in glaucoma therapy by its products for telemetric, 24 hour monitoring of intraocular pressure, allowing personalized patient management.
To the complete profileof Implandata Ophthalmic Products
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
To the complete profileof trans.duodenal.concepts
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
To the complete profileof Signatope
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
To the complete profileof Tacalyx
Nuuron was founded by Fabian Queisner and Dr. Markus Müschenich. The scientific director is Priv.-Doz. Dr. Julian Keil. The Nuuron team consists of experts in the fields of neuroscience, medicine, …
To the complete profileof Nuuron
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx